Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01970722 · ClinicalTrials.gov registry record · Phase 1

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

A Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 1
Development phase
40
Enrollment target
4
Study locations

NCT01970722 is a Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 40 participants, below the 123-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (67% lower). The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01970722, a Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
4
Study locations

Study Summary

This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal cancer. Giving a dose of heated chemotherapy into the abdomen during surgery that is done to remove ovarian, fallopian tube, uterine, or peritoneal cancer may help lower the risk of the cancer coming back. Giving unheated chemotherapy drugs directly into the abdomen after surgery may kill more tumor cells.

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • OTHER Laboratory Biomarker Analysis
  • DRUG Paclitaxel
  • DRUG Gemcitabine Hydrochloride

Study Locations (4)

California

  • City of Hope Corona - Corona
  • City of Hope Medical Center - Duarte
  • City of Hope Upland - Upland

Indiana

  • Parkview Hospital Randallia - Fort Wayne

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2014-05-19
Est. Completion 2027-01-05
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

What the Registry Record Tells You About NCT01970722

The ClinicalTrials.gov registry entry for NCT01970722 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (67% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT01970722 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Indiana.

Frequently Asked Questions

What is clinical trial NCT01970722 about?

NCT01970722 is a clinical study titled "Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer". This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal cancer. Giving a dose of heated chemotherapy into the abdomen during surgery ...

What is the current status of trial NCT01970722?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-05-19. Estimated completion is 2027-01-05.

What conditions does trial NCT01970722 study?

This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Uterine Corpus Carcinoma.

What interventions are being tested in trial NCT01970722?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Gemcitabine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT01970722?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01970722 being conducted?

This trial has 4 study locations across California, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Recurrent Ovarian Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.